Market Cap 720.24M
Revenue (ttm) 0.00
Net Income (ttm) -38.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 1,550,100
Avg Vol 2,146,056
Day's Range N/A - N/A
Shares Out 73.27M
Stochastic %K 48%
Beta -0.52
Analysts Strong Sell
Price Target $19.71

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
DiamondDog33
DiamondDog33 Jul. 4 at 7:01 PM
$CADL THE DOG IS HEADING TO SONIC FOR THE TRADITION..... HAPPY 4th BOTH BULL AND BEAR and REALIST!!!!!
0 · Reply
stu4
stu4 Jul. 4 at 6:57 PM
$CADL the liar of cadl . Dilution3 times in 4 years makes your stock worth less . Simple math , but you keep telling yourself $5.25 .., loser
0 · Reply
eagles155
eagles155 Jul. 4 at 6:33 PM
$CADL Happy July 4th! Remember what we have:
1 · Reply
telomerase
telomerase Jul. 4 at 3:01 PM
$CADL Disco Stu4 whines about dilution at reasonable prices in CADL, then lauds SLS for funding itself with low-priced warrants. SLS, with a $3 billion market cap based on no Phase 3 data at all. SLS DOES have a far superior pump network, but that was also true of its ill-fated predecessor GALE. The reason that CADL hasn't already filed its BLA is that they made a decision years ago to wait for the blinded Phase 3 results before spending on manufacturing. As it turned out that decision caused a major delay... of course if the trial had failed and they had already built out manufacturing, that wouldn't have looked too bright either. But anyway, the delay is ending in 4th quarter of this year. Stu also keeps "forgetting" that Tak worked for GSK for seven years. We still need a real bear on this board... Stu and his other IDs just repeat their old talking points from 2025, without ever commenting on what's going on. He isn't even allowed to say the words "Phase 3 trial in NSCLC".
2 · Reply
John_morrris
John_morrris Jul. 4 at 1:55 PM
$IBRX $CADL HAPPY INDEPENDENCE DAY!!
0 · Reply
Bullisch_150
Bullisch_150 Jul. 4 at 1:39 PM
$CADL we are to the moon with a big buyout
0 · Reply
gmania
gmania Jul. 4 at 1:37 PM
$CADL Thanks Xander. Happy 4th
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:30 PM
$CADL https://seekingalpha.com/article/4919788-candel-therapeutics-an-overlooked-late-stage-biotech-with-real-potential
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:28 PM
$CADL Why Now Is The Right Time CADL is approaching several major catalysts. The company has prostate cancer BLA work underway, supportive biomarker data expected, a Phase III NSCLC trial initiated, and mature CAN-3110 repeat-dose glioma data expected later. At the same time, its cash runway gives it enough time to reach these events without immediate balance sheet pressure. This is why I think now is the right time to look at the company. The stock still appears to trade like a speculative biotech, while the company is moving toward a regulatory event that could change how investors value it.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:28 PM
$CADL strong buy 👌
0 · Reply
Latest News on CADL
Candel Therapeutics Transcript: AGM 2026

Jun 23, 2026, 10:00 AM EDT - 11 days ago

Candel Therapeutics Transcript: AGM 2026


Candel Therapeutics price target raised to $9 from $7 at BofA

2026-05-18T19:30:09.000Z - 6 weeks ago

Candel Therapeutics price target raised to $9 from $7 at BofA


Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 7 weeks ago

Candel Therapeutics Transcript: Study result


Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 7 weeks ago

Candel Therapeutics Slides: Study result


Candel Therapeutics Press release: Study result

May 15, 2026, 1:00 PM EDT - 7 weeks ago

Candel Therapeutics Press release: Study result


Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Candel Therapeutics Earnings release: Q1 2026


Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Candel Therapeutics Quarterly report: Q1 2026


Candel Therapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 8:05 AM EDT - 7 weeks ago

Candel Therapeutics to Present at Upcoming Investor Conferences


Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-18T10:22:07.000Z - 3 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi


Candel Therapeutics Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:41.000Z - 4 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year


Candel Therapeutics sees cash runway into 1Q28

2026-03-12T12:11:01.000Z - 4 months ago

Candel Therapeutics sees cash runway into 1Q28


Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Earnings release: Q4 2025


Candel Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Annual report: Q4 2025


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:29.000Z - 4 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 4 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 9:40 PM EST - 4 months ago

Candel Therapeutics Announces Pricing of Public Offering


Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T22:10:17.000Z - 4 months ago

Candel Therapeutics announces $100M royalty funding agreement


Candel Therapeutics announces $100M common stock offering

2026-02-19T21:13:42.000Z - 4 months ago

Candel Therapeutics announces $100M common stock offering


Candel Therapeutics Slides: Corporate Presentation

Dec 10, 2025, 7:00 AM EST - 7 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 7 months ago

Candel Therapeutics Transcript: R&D Day 2025


Candel Therapeutics Press release: FY 2025

Dec 5, 2025, 11:00 AM EST - 7 months ago

Candel Therapeutics Press release: FY 2025


Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

2025-11-13T13:31:40.000Z - 8 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year


Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Candel Therapeutics Quarterly report: Q3 2025


Candel Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Candel Therapeutics Earnings release: Q3 2025


Candel Therapeutics Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 8 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics initiated with an Overweight at Stephens

2025-10-27T20:35:14.000Z - 8 months ago

Candel Therapeutics initiated with an Overweight at Stephens


Candel Therapeutics appoints Pulendran to Candel’s RAB

2025-10-16T12:20:35.000Z - 9 months ago

Candel Therapeutics appoints Pulendran to Candel’s RAB


Candel Therapeutics enters into $130M term loan facility

2025-10-14T12:31:44.000Z - 9 months ago

Candel Therapeutics enters into $130M term loan facility

TRIN


Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 9 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting


Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Quarterly report: Q2 2025


Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Earnings release: Q2 2025


Candel Therapeutics Registration statement: Registration Filing

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Registration statement: Registration Filing


Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025


Candel Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


Candel Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Annual report: Q4 2024


Candel Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q4 2024


DiamondDog33
DiamondDog33 Jul. 4 at 7:01 PM
$CADL THE DOG IS HEADING TO SONIC FOR THE TRADITION..... HAPPY 4th BOTH BULL AND BEAR and REALIST!!!!!
0 · Reply
stu4
stu4 Jul. 4 at 6:57 PM
$CADL the liar of cadl . Dilution3 times in 4 years makes your stock worth less . Simple math , but you keep telling yourself $5.25 .., loser
0 · Reply
eagles155
eagles155 Jul. 4 at 6:33 PM
$CADL Happy July 4th! Remember what we have:
1 · Reply
telomerase
telomerase Jul. 4 at 3:01 PM
$CADL Disco Stu4 whines about dilution at reasonable prices in CADL, then lauds SLS for funding itself with low-priced warrants. SLS, with a $3 billion market cap based on no Phase 3 data at all. SLS DOES have a far superior pump network, but that was also true of its ill-fated predecessor GALE. The reason that CADL hasn't already filed its BLA is that they made a decision years ago to wait for the blinded Phase 3 results before spending on manufacturing. As it turned out that decision caused a major delay... of course if the trial had failed and they had already built out manufacturing, that wouldn't have looked too bright either. But anyway, the delay is ending in 4th quarter of this year. Stu also keeps "forgetting" that Tak worked for GSK for seven years. We still need a real bear on this board... Stu and his other IDs just repeat their old talking points from 2025, without ever commenting on what's going on. He isn't even allowed to say the words "Phase 3 trial in NSCLC".
2 · Reply
John_morrris
John_morrris Jul. 4 at 1:55 PM
$IBRX $CADL HAPPY INDEPENDENCE DAY!!
0 · Reply
Bullisch_150
Bullisch_150 Jul. 4 at 1:39 PM
$CADL we are to the moon with a big buyout
0 · Reply
gmania
gmania Jul. 4 at 1:37 PM
$CADL Thanks Xander. Happy 4th
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:30 PM
$CADL https://seekingalpha.com/article/4919788-candel-therapeutics-an-overlooked-late-stage-biotech-with-real-potential
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:28 PM
$CADL Why Now Is The Right Time CADL is approaching several major catalysts. The company has prostate cancer BLA work underway, supportive biomarker data expected, a Phase III NSCLC trial initiated, and mature CAN-3110 repeat-dose glioma data expected later. At the same time, its cash runway gives it enough time to reach these events without immediate balance sheet pressure. This is why I think now is the right time to look at the company. The stock still appears to trade like a speculative biotech, while the company is moving toward a regulatory event that could change how investors value it.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:28 PM
$CADL strong buy 👌
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 4 at 1:27 PM
0 · Reply
Kittyc803
Kittyc803 Jul. 4 at 11:50 AM
$CADL Happy 4th of July 🇺🇸🇺🇸🇺🇸🇺🇸 everyone 👍👍
0 · Reply
stu4
stu4 Jul. 4 at 10:59 AM
$CADL $SLS once again this poor sob, can’t read …he makes up crap and it all comes back to bite him in the ass As it has at $CADL …dilution occurred 3 times on his dubious watch , making his shares worth 60% less in a but out , BUT he can’t do math either , so he waits for TAK to drop another offering come Dec 2026 !!! WHY ???? A professor can never give up on laundering money from the public , whether thru endowments or public offerings to keep his dream alive . As for business, the skill set isn’t there, Pfizer is on the hunt and TAK is too dumb to do a deal ! His Phase 3 “ stuff” should have been submitted long ago , he must be massaging it !! Get John Maraganore to take this to a board table and reward those , lol, at 50% discount from TAK , under John !!! You losers . As for SLS, they have warrants to collect on, lol, provided the strike price is “ wonderful “ that they exercise and walk with 50% profit !!! Guess there is a business man there !
1 · Reply
Greyhound9
Greyhound9 Jul. 4 at 8:49 AM
$CADL Happy July 4th, enjoy it, and make it a beautiful day, everyone.
0 · Reply
TheBigM
TheBigM Jul. 4 at 12:21 AM
$CADL bullish as fuck boys
2 · Reply
moneymaker444
moneymaker444 Jul. 3 at 9:50 PM
$CADL from king .. This reply is for sunshine...from collected data and algorithm....of last pr in May run up...i took the old 52wk high of 9.27 to 7.48 low...equals 1.79 retracement...this run to 11.36 to 9.57 low is u guessed it. 1.79 retracement...i dont talk about the other side of the trade ( the red side) any longer on the board because it gets up in some folks feeling ..but there's always 2 side to the trade...my bad for not getting back to u immediately...was busy on the road...
2 · Reply
Dkll303
Dkll303 Jul. 3 at 6:58 PM
$CADL And TAK the hack , will fcuk this up, like he did Kintai !!!! And Omega therapeutics
0 · Reply
StreakGeek
StreakGeek Jul. 3 at 6:15 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $GALT $ENVX $CADL strong opportunity
1 · Reply
stu4
stu4 Jul. 3 at 5:42 PM
$SLS tell them over at the fcuked up $CADL camp , lol They think they have a winner !! @Dmd32 a dentist cool and there is leftymd here as well
1 · Reply
StreakGeek
StreakGeek Jul. 3 at 5:21 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $AUPH $TLRY $CADL loading Monday
2 · Reply
StreakGeek
StreakGeek Jul. 3 at 3:41 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $RDW $CADL $TMC top opportunities
0 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Jul. 3 at 2:13 PM
$CADL Wishing a Happy Revolution Day to our friends in the US
0 · Reply